StreetAlpha.app
Home › Stocks › QTTB

Q32 Bio Inc. (QTTB)

Healthcare
$8.63
▲ +4.10%
LAST CLOSE · NOV 17

Q32 Bio develops experimental antibody treatments for alopecia areata and other autoimmune and inflammatory diseases. It last closed at $8.63 on Nov 17, up 4.10% on the day. The average 12-month price target from 3 analysts is $34.33 (+297.8% from the last close), with a high of $40.00 and a low of $29.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is QTTB in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
$53.7M
Net income
$29.8M
55.5% margin
EPS (diluted)
$2.42
Free cash flow
−$33.5M
−62.4% margin
Valuation
Market cap
$258.2M
29.9M shares
P/E
3.6
Price over 12 month EPS
Price to sales
4.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$289.6M
At Sep 30
Shareholder equity
$287.7M
Shares outstanding
29.9M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $34.0M$34.0MFY2021FY2022: $3.2M$3.2MFY2022FY2023: −$6.7M−$6.7MFY2023FY2024: $0$0FY2024FY2025: $53.7M$53.7MFY2025

From QTTB's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 4).

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on QTTB in the past 90 days
Average 12-month target
$34.33
▲ 297.8% upside

Based on 3 analysts who set a price target on QTTB in the past 90 days. The average target is $34.33, with a high of $40.00 and a low of $29.00, compared with the last close of $8.63.

Low $29.00Avg $34.33High $40.00
Blue marker: last close $8.63
Highest target$40.00
Average target$34.33
Lowest target$29.00
Latest rating changes
Leerink PartnersInitiated
Oct 12Buy$40
JefferiesInitiated
Sep 28Buy$29
Morgan StanleyInitiated
Aug 24Buy$34
HC Wainwright & Co.Maintained
Jul 28Buy$36
Wells FargoUpgrade
Jul 13Buy$66
DateFirmActionRatingPrice target
Oct 12Leerink PartnersInitiatedBuy$40
Sep 28JefferiesInitiatedBuy$29
Aug 24Morgan StanleyInitiatedBuy$34
Jul 28HC Wainwright & Co.MaintainedBuy$36
Jul 13Wells FargoUpgradeBuy$66
Loading…

Technical Analysis

QTTB · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 3% below its 20 day and 5% below its 50 day average. It is 10% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the Pivot at $8.47, and the nearest resistance the 20 day average at $8.85.

Short trendNeutral
Long trendNeutral
MomentumNeutral
StretchNormal
VolatilityLow, 6.4%/day
Key levels
$23.5752 week high+173.1%
$12.04100 day average+39.5%
$9.53200 day average+10.4%
$9.0850 day average+5.2%
$9.01Swing high (Oct 22)+4.4%
$8.88Pivot R1+2.9%
$8.8520 day average+2.5%
$8.63Last close
$8.47Pivot−1.9%
$8.23Pivot S1−4.6%
$8.23Swing low (Nov 5)−4.6%
$1.9152 week low−77.9%
Indicators
RSI (14)45.01Middle of its rangeNeutral
MACD-0.12Above its signal lineBullish
Stochastic23.1Middle of its rangeNeutral
ADX (14)17.9No clear trend
Williams %R-66.5Oversold below −80, overbought above −20Neutral
CCI (20)-114.5Oversold below −100, overbought above 100Oversold
Rate of change−1.5%Change over 10 sessionsBearish
ATR (14)$0.56Typical daily range, 6.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for QTTB

What happened before

See how QTTB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow QTTB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How QTTB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in QTTB in the last 90 days.

Loading…

See today’s whale options flow across the market →

QTTB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲71 buying vs 32 selling
  • ▲Held by funds +31.1 pts
  • ▲Funds holding +33
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10572+45.8%
In funds' top 1013−66.7%
Held by funds105.3%74.2%+31.1 pts
New / increased48 / 2328 / 18+54.3%
Reduced / sold out16 / 1613 / 8+52.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See QTTB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QTTB is in one of them and how their past QTTB trades turned out.

QTTB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered QTTB in an article yet. Here's the latest on the wider market.

About Q32 Bio

Q32 Bio is a biotechnology company in Waltham, Massachusetts, that develops experimental biologic medicines for patients with alopecia areata, a condition that causes hair loss, and other autoimmune and inflammatory diseases. Its lead candidate, bempikibart, is an antibody designed to block two immune signals and is being tested in clinical trials. The company also holds a tissue-targeted complement inhibitor platform, which it is evaluating for strategic options.

Headquarters
Waltham, MA